TCL Archive Phase II Study Meets Primary Endpoint, Demonstrating Overall Survival of 5.2 Months September 27, 2013
TCL Archive MSK Investigators Report Sialic Acid Test 95% Accurate; Negative Immunotherapy Results Told June 13, 1980
TCL Archive Perjeta, Herceptin & Docetaxel Combination Extended Survival in HER2-Positive Disease December 28, 2012